Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor: early-phase trial registry
104 of 197 indexed Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #53 of 28,707 conditions by registered trial count.
197 US clinical trials · 104 currently recruiting · #53 of 28,707 conditions by registered trial count
Solid Tumor: 197 US clinical trials tracked, 104 recruiting.
Solid Tumor is the subject of 197 registered US clinical trials on ClinicalTrials.gov, 104 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 165 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition solid-tumor
OPEN 104 | RECR 53% | LATE 4 | EARLY 165 | RANK #53 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Metastatic Breast Cancer (53% recruiting · 140 trials)
Solid Tumor lists 104 open slots (53% of 197 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumor is recruiting above its size-band peers.
104 of 197 indexed trials (52.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumor trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 11 of 197 trials (5.6%). 149 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumor enrolment sits around 80 participants.
Median target enrolment is 80 among the 197 trials that report a genuine target (sentinel values excluded). 108 of those (54.8%) plan for fewer than 100 participants.
-
Solid Tumor research is mostly interventional.
179 interventional and 18 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
197 total, page 4 of 4
Illness Management and Parental Adjustment to Cancer Treatment
Children's Hospital Medical Center, Cincinnati
NCT02505165
Validating Pain Scales in Children and Young Adults
National Cancer Institute (NCI)
NCT01639950
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology
NCT03013218
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT02791334
Durvalumab Long-Term Safety and Efficacy Study
AstraZeneca
NCT04078152
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Processa Pharmaceuticals
NCT02030067
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
NCT01752920
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin
NCT02705105
Individualized Stereotactic Body Radiotherapy of Liver Metastases
Massachusetts General Hospital
NCT01239381
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT03311412
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Gilead Sciences
NCT02216409
A Study of of MORAb-004 in Subjects With Solid Tumors
Morphotek
NCT00847054
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00786838
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
Fujifilm Pharmaceuticals U.S.A.
NCT02454010
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Traws Pharma
NCT01168011
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
ImmunoGen
NCT00721669
AO-176 in Multiple Solid Tumor Malignancies
Arch Oncology
NCT03834948
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
Dana-Farber Cancer Institute
NCT00215501
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
David Bajor, MD
NCT02861300
Indocyanine Green for Solid Tumors
University of Pennsylvania
NCT02280954
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
Debiopharm International
NCT04122625
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Astellas Pharma
NCT01284192
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Syndax Pharmaceuticals
NCT03238027
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT04666688
The Good Patient Study
St. Jude Children's Research Hospital
NCT02199548
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Athenex
NCT02730481
Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant
St. Jude Children's Research Hospital
NCT01540175
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
Bristol-Myers Squibb
NCT00803556
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
NCT01337765
Eribulin and Lenvatinib in Advanced Solid Tumors
Virginia G. Kaklamani
NCT02640508
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
National Cancer Institute (NCI)
NCT01240590
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
NCT00638898
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT03489343
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
Genentech
NCT01363024
Pain Control in Hospice Patients With Cancer-Related Pain
Vanderbilt-Ingram Cancer Center
NCT00609297
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03051477
Solid Tumors Using Ixabepilone and Dasatinib
Medstar Health Research Institute
NCT00717704
HCW9218 in Select Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT05322408
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Da Zen Theranostics
NCT04970992
Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients
St. Jude Children's Research Hospital
NCT01383473
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Washington University School of Medicine
NCT02352844
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03758781
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT04601402
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma
NCT01165905
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
Immatics US
NCT03247309
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
Virginia Commonwealth University
NCT03220854
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 150 |
| Phase 2 | 15 |
| Phase 3 | 1 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumor page
197 registered trials, 104 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 104 Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor condition card totals 197 registered trials; most-linked intervention Nivolumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.